Broadway Financial (NASDAQ:BYFC) reported quarterly earnings of $0.02 per share.
Evelo Biosciences’ Atopic Dermatitis Study Cohort Misses Primary Goal Again, Shuts Study, Lays Off More Staff
Evelo Biosciences Inc (NASDAQ: EVLO) said its fourth cohort of the EDP1815 Phase 2 trial in atopic dermatitis, consistent with the first three cohorts, failed to meet the primary endpoint of the proportion of patients who achieve an EASI-50 response at week 16.